673 results on '"Trümper, L."'
Search Results
2. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
3. Role and responsibility of oncologists in assisted suicide. Practice and views among members of the German Society of Haematology and Medical Oncology
4. Allogeneic transplantation in T‐cell lymphoma: Lessons from the AATT study
5. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL
6. Microenvironmental interactions between endothelial and lymphoma cells: a role for the canonical WNT pathway in Hodgkin lymphoma
7. WNT5A: a motility-promoting factor in Hodgkin lymphoma
8. Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL
9. Obesity negatively impacts outcome in elderly female patients with aggressive B‐cell lymphomas treated with R‐CHOP‡: results from prospective trials of the German high grade non‐Hodgkinʼs lymphoma trial group
10. Nodale aggressive Non-Hodgkin-Lymphome
11. Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
12. Maligne Lymphome
13. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
14. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma
15. Aggressive B-Zell-Lymphome bei älteren Patienten: Kurative oder palliative Behandlungsstrategie?
16. S3 - Leitlinie zur Diagnostik, Therapie und Nachsorge für erwachsene Patient*innen mit einem diffusen großzelligen B-Zell-Lymphom und verwandten Entitäte
17. Treatment of Centroblastic-Centrocytic and Centrocytic Lymphomas at Advanced Stages — Results of the German Low-Grade Lymphoma Study Group
18. Therapiestrategien bei hochmalignen Non-Hodgkin-Lymphomen
19. Therapie der zentroblastisch-zentrozytischen und zentrozytischen Lymphome in fortgeschrittenen Stadien — Ergebnisse der Deutschen Studiengruppe zur Behandlung niedrigmaligner Lymphome
20. Wnt 5a Signaling Is Critical for Macrophage-Induced Invasion of Breast Cancer Cell Lines
21. Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens
22. Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network
23. High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma
24. Non-Hodgkin-Lymphome: Bewährtes und Neues
25. SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status
26. Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial
27. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
28. Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin’s lymphoma
29. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens
30. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin’s lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)
31. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
32. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells
33. Differenzialdiagnose und -abklärung von Lymphknotenvergrößerungen
34. Diagnostik und Stadieneinteilung bei Non-Hodgkin-Lymphomen
35. The interleukin-10 gene promoter polymorphism −1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma
36. Asymptomatische 32-jährige Raucherin mit persistierender Lymphozytose
37. Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma—role of radioimmunotherapy
38. Correction:High-risk additional chromosomal abnormalities at low blast counts herald death by CML (Leukemia, (2020), 34, 8, (2074-2086), 10.1038/s41375-020-0826-9)
39. Controversies in the Treatment of Peripheral T-cell Lymphoma
40. Targeted-Therapie: Neue Zielstrukturen und Substanzen in der Behandlung maligner Lymphome
41. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis
42. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia
43. Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect
44. Elevated Concentrations of Serum Relaxin are Associated with Metastatic Disease in Breast Cancer Patients
45. A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma
46. Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients?
47. Retroperitoneal fibrosis as manifestation of chronic GVHD after allogeneic hematopoietic SCT
48. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia
49. Leukemia- and lymphoma-associated genetic aberrations in healthy individuals
50. Assessment of clonality of rosetting T lymphocytes in Hodgkin's disease by single-cell polymerase chain reaction: detection of clonality in a polyclonal background in a case of lymphocyte predominance Hodgkin's disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.